Correlation of Immune-Related Adverse Events and Effects of Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung Cancer

PURPOSE: The effects of immune checkpoint inhibitors have been reported to be linked with immune-related adverse events (irAEs). In patients with advanced non-small-cell lung cancer, who tested positive for programmed death-ligand 1 (PD-L1), pembrolizumab, an immune checkpoint inhibitor can be used...

Descripción completa

Detalles Bibliográficos
Autores principales: Noguchi, Susumu, Suminaga, Keiichiro, Kaki, Takahiro, Kawachi, Hiroaki, Fukao, Akari, Terashita, Satoshi, Horikawa, Sadao, Ikeue, Tatsuyoshi, Sugita, Takakazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7367935/
https://www.ncbi.nlm.nih.gov/pubmed/32765147
http://dx.doi.org/10.2147/LCTT.S254146

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7367935/
https://www.ncbi.nlm.nih.gov/pubmed/32765147
http://dx.doi.org/10.2147/LCTT.S254146

Ejemplares similares